USD 2.24
(-0.24%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 12.4 Million USD | 25.04% |
2022 | 9.92 Million USD | 5.11% |
2021 | 9.44 Million USD | -27.28% |
2020 | 12.98 Million USD | 81.48% |
2019 | 7.15 Million USD | -10.73% |
2018 | 8.01 Million USD | -28.64% |
2017 | 11.23 Million USD | 6.51% |
2016 | 10.54 Million USD | -10.78% |
2015 | 11.81 Million USD | -10.13% |
2014 | 13.15 Million USD | 405.42% |
2013 | 2.6 Million USD | 29.93% |
2012 | 2 Million USD | -17.07% |
2011 | 2.41 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 3.73 Million USD | 18.74% |
2024 Q1 | 3.14 Million USD | -10.29% |
2023 FY | 12.4 Million USD | 25.04% |
2023 Q3 | 3.13 Million USD | 9.55% |
2023 Q2 | 2.85 Million USD | -1.94% |
2023 Q4 | 3.5 Million USD | 11.93% |
2023 Q1 | 2.91 Million USD | 25.86% |
2022 FY | 9.92 Million USD | 5.11% |
2022 Q2 | 2.5 Million USD | 2.45% |
2022 Q1 | 2.44 Million USD | 38.14% |
2022 Q3 | 2.65 Million USD | 5.91% |
2022 Q4 | 2.31 Million USD | -12.76% |
2021 Q3 | 2.71 Million USD | 16.24% |
2021 FY | 9.44 Million USD | -27.28% |
2021 Q1 | 2.61 Million USD | 21.94% |
2021 Q2 | 2.33 Million USD | -10.65% |
2021 Q4 | 1.77 Million USD | -34.81% |
2020 Q3 | 2.07 Million USD | -70.14% |
2020 Q2 | 6.96 Million USD | 288.3% |
2020 Q1 | 1.79 Million USD | 25.95% |
2020 FY | 12.98 Million USD | 81.48% |
2020 Q4 | 2.14 Million USD | 3.16% |
2019 Q4 | 1.42 Million USD | -12.98% |
2019 Q1 | 1.96 Million USD | 11.39% |
2019 Q2 | 2.12 Million USD | 7.81% |
2019 Q3 | 1.63 Million USD | -22.93% |
2019 FY | 7.15 Million USD | -10.73% |
2018 Q4 | 1.76 Million USD | 16.15% |
2018 Q3 | 1.52 Million USD | -33.98% |
2018 FY | 8.01 Million USD | -28.64% |
2018 Q1 | 2.41 Million USD | -9.08% |
2018 Q2 | 2.3 Million USD | -4.61% |
2017 FY | 11.23 Million USD | 6.51% |
2017 Q4 | 2.65 Million USD | -28.17% |
2017 Q3 | 3.7 Million USD | 28.11% |
2017 Q2 | 2.88 Million USD | 45.92% |
2017 Q1 | 1.98 Million USD | -14.8% |
2016 Q3 | 2.16 Million USD | -25.14% |
2016 FY | 10.54 Million USD | -10.78% |
2016 Q2 | 2.89 Million USD | -8.09% |
2016 Q1 | 3.15 Million USD | 23.59% |
2016 Q4 | 2.32 Million USD | 7.14% |
2015 Q4 | 2.55 Million USD | -4.0% |
2015 Q2 | 3.16 Million USD | -8.15% |
2015 Q1 | 3.44 Million USD | 18.21% |
2015 Q3 | 2.65 Million USD | -16.02% |
2015 FY | 11.81 Million USD | -10.13% |
2014 Q2 | 3.49 Million USD | 19.48% |
2014 Q3 | 3.82 Million USD | 9.43% |
2014 Q4 | 2.91 Million USD | -23.73% |
2014 FY | 13.15 Million USD | 405.42% |
2014 Q1 | 2.92 Million USD | 84.88% |
2013 Q4 | 1.58 Million USD | 225.54% |
2013 Q1 | 332.03 Thousand USD | -49.84% |
2013 FY | 2.6 Million USD | 29.93% |
2013 Q2 | 203.42 Thousand USD | -38.73% |
2013 Q3 | 485.59 Thousand USD | 138.71% |
2012 FY | 2 Million USD | -17.07% |
2012 Q1 | 502.42 Thousand USD | 0.0% |
2012 Q2 | 360.33 Thousand USD | -28.28% |
2012 Q3 | 477.74 Thousand USD | 32.58% |
2012 Q4 | 661.91 Thousand USD | 38.55% |
2011 FY | 2.41 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bright Green Corporation | 8.25 Million USD | -50.368% |
Alpha Teknova, Inc. | 45.85 Million USD | 72.94% |
ANI Pharmaceuticals, Inc. | 195.98 Million USD | 93.668% |
Aquestive Therapeutics, Inc. | 44.85 Million USD | 72.333% |
Collegium Pharmaceutical, Inc. | 159.2 Million USD | 92.205% |
Cosmos Health Inc. | 26.18 Million USD | 52.6% |
Journey Medical Corporation | 54.59 Million USD | 77.269% |
Embecta Corp. | 528.4 Million USD | 97.651% |
Esperion Therapeutics, Inc. | 271.89 Million USD | 95.436% |
Dynavax Technologies Corporation | 219.14 Million USD | 94.337% |
Intra-Cellular Therapies, Inc. | 590 Million USD | 97.897% |
Pacira BioSciences, Inc. | 326.37 Million USD | 96.198% |
PainReform Ltd. | 9.58 Million USD | -29.483% |
Sunshine Biopharma, Inc. | 13.12 Million USD | 5.447% |
Sunshine Biopharma, Inc. | 13.12 Million USD | 5.447% |
SCYNEXIS, Inc. | 51.84 Million USD | 76.065% |
Safety Shot Inc | 12.1 Million USD | -2.477% |
China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -304.33% |
Procaps Group, S.A. | 199.47 Million USD | 93.779% |
Theratechnologies Inc. | 72.75 Million USD | 82.943% |
Harrow Health, Inc. | 89.97 Million USD | 86.207% |
Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -31.375% |
Biofrontera Inc. | 39.95 Million USD | 68.944% |
DURECT Corporation | 43.71 Million USD | 71.612% |
Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 97.654% |
Cronos Group Inc. | 96.7 Million USD | 87.168% |
OptiNose, Inc. | 85.1 Million USD | 85.418% |
Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 94.654% |
Kala Pharmaceuticals, Inc. | 39.15 Million USD | 68.305% |
RedHill Biopharma Ltd. | -9.56 Million USD | 229.794% |
Organogenesis Holdings Inc. | 314.13 Million USD | 96.05% |
Guardion Health Sciences, Inc. | 9.73 Million USD | -27.529% |
Cumberland Pharmaceuticals Inc. | 43.04 Million USD | 71.168% |
Radius Health, Inc. | 265.92 Million USD | 95.333% |
Universe Pharmaceuticals INC | 13.84 Million USD | 10.347% |
ProPhase Labs, Inc. | 37.85 Million USD | 67.215% |
Phibro Animal Health Corporation | 260.29 Million USD | 95.233% |
Procaps Group S.A. | 187.24 Million USD | 93.373% |
Alvotech | 285.43 Million USD | 95.652% |
TherapeuticsMD, Inc. | 9.82 Million USD | -26.307% |
Viatris Inc. | 5.96 Billion USD | 99.792% |
Rockwell Medical, Inc. | 15.37 Million USD | 19.282% |
Aytu BioPharma, Inc. | 59.84 Million USD | 79.262% |
SIGA Technologies, Inc. | 22.04 Million USD | 43.703% |
Tilray Brands, Inc. | 251.35 Million USD | 95.063% |
Lifecore Biomedical, Inc. | 49.03 Million USD | 74.694% |
Shineco, Inc. | 17.94 Million USD | 30.858% |
PetIQ, Inc. | 192.72 Million USD | 93.561% |
Regencell Bioscience Holdings Limited | 3.99 Million USD | -210.93% |
Incannex Healthcare Limited | 30.05 Million USD | 58.707% |
Neurocrine Biosciences, Inc. | 1.59 Billion USD | 99.223% |
Alimera Sciences, Inc. | 62.64 Million USD | 80.189% |
Silver Spike Investment Corp. | 762.49 Thousand USD | -1527.511% |
Assertio Holdings, Inc. | 368.58 Million USD | 96.633% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -110.849% |
Petros Pharmaceuticals, Inc. | 17.8 Million USD | 30.316% |
Clever Leaves Holdings Inc. | 21.16 Million USD | 41.378% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | 41.025% |
Avadel Pharmaceuticals plc | 164.96 Million USD | 92.477% |
Hempacco Co., Inc. | 7.59 Million USD | -63.361% |
Talphera, Inc. | 11.99 Million USD | -3.465% |
Alvotech | 285.43 Million USD | 95.652% |
Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 91.181% |
Lantheus Holdings, Inc. | 344.9 Million USD | 96.402% |
Currenc Group, Inc. | 24 Million USD | 48.298% |
Kamada Ltd. | 45.42 Million USD | 72.682% |
Indivior PLC | 911 Million USD | 98.638% |
Flora Growth Corp. | 10.57 Million USD | -17.304% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | 41.025% |
Evolus, Inc. | 189.75 Million USD | 93.46% |
HUTCHMED (China) Limited | 436.23 Million USD | 97.155% |
Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 91.949% |
Akanda Corp. | 3.48 Million USD | -256.24% |